The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
i have him bloked, lol is he biteing?
i dont know why anyone responds to him or his kind
i put him in his green box weeks ago.
the green boxes are very useful . it is a good sign that something is about to happen when there are 16+ on a page LOL
GLA
This is aim of course if you believe go for it the stuff is all there make your mind up so either go or move on
U
interesting read to all new investers,
so who do you trust??
mysteryguy, or these bunch of very succsesful bussines men?
as Chiroscience, Celsis, ReNeuron, Vectura, Biovex and Merlin Biosciences Ltd. Appointed an OBE in 1995 for services to medical bioscience, he was knighted in 2001 for services to bioscience and enterprise. Latterly he was founder of Arix Bioscience plc (LSE: ARX), of the oncology specialist Ellipses Pharma Limited, and of Excalibur Healthcare Services Ltd.
The Business:
Igraine targets innovative technologies and discoveries using an extensive network of scientific, industry, and academic contacts, including eminent scientists and key opinion leaders. Its network also enables it to pursue relationships with pharmaceutical companies which are both a potential source of innovative opportunities and potential acquirers.
The team has developed relationships over many years with leading universities and other academic and research institutions globally and maintains close working relationships with premier professional advisers and fund managers.
Igraine works with institutional and individual investment partners and has a formal co-investment agreement with Excalibur Healthcare Services Ltd.
Igraine has invested in Excalibur Medicines Ltd (“EML”), a subsidiary of Excalibur Healthcare Services Ltd. EML has secured exclusive rights to and owns the COVID-19 patents on a drug, AZD1656, which is being developed as a potential therapeutic for diabetics suffering from COVID-19.
As there are very few new therapeutics in development for COVID-19 and associated virally transmitted diseases (most research is in combining existing treatments), this has the potential to be highly attractive to big pharma and biotech buyers. Further, if the trials are successful, it is likely the drug will be effective for the general population in COVID -19 and in other respiratory diseases.
Developments Intended by the Company’s Financial Year-End:
Excalibur Medicines Limited, a subsidiary of Excalibur Healthcare Services Ltd., announced that the clinical team will report on the ARCADIA trial in September.
Excalibur Medicines Ltd (“EML”) has secured exclusive rights to and owns the patents on a drug, AZD1656, which is being developed as a potential therapeutic for people with diabetes suffering from COVID-19. The ARCADIA trial which took place across 31 sites was completed in July this year.
The research project was arranged and structured by Professor Sir Chris Evans, Chairman and CEO of Excalibur Healthcare Services, through its subsidiary, Excalibur Medicines Ltd. Sir Chris worked closely with Professor John Martin and his team at St George Street, a UK-based biomedical research charity, which secured the initial project and permission to run the trial from AstraZeneca.
The aim of the ARCADIA trial is to determine whether AZD1656 improves clinical outcomes in diabetic patients hospitalised with COVID-19. The World Health Organisation’s (WHO) 8-point Ordinal Scale for Clinical Improvement will be used as the standard methodology for measurin
Oscillate Plc - Interim Results For The Six Months Ended 31 May 2021
09/03/2021 | 05:05am EST
share with twitter
share with LinkedIn
share with facebook
3 September 2021
Oscillate PLC (Formerly known as DiscovOre PLC)
(“Oscillate”or the “Company")
Interim Results For The Six Months Ended 31 May 2021
Burns Singh Tennent-Bhohi, Chairman’s Statement
I am pleased to present the interim results for Oscillate plc (AQSE: MUSH) for the period ending 31 May 2021. Of most significance, and a defining moment for the Company during the period, was the completion of a £3,500,000 brokered placing led by the Company’s broker, Peterhouse Capital, and serial entrepreneur Chris Akers. In conjunction with this financing, the Company announced its intention to adopt a broader investment policy to include medical psychedelics, and the Board welcomed a new officer in Narisha Ragoonanthun, as Jeremy Ross resigned from the Board of Directors.
In the months to follow, the Company has been focusing heavily on creating and developing a premier alternative health investment issuer that can offer investors a unique blend of optionality.
Importantly, as the Company enters this emerging category of investment, a great degree of attention has been placed on ensuring that potential investment opportunities offer the ability to generate material value, but also credible alignment, as the Company builds important foundations that can position Oscillate to build a broad audience in a market with limited access in direct market exposure.
In July 2021, Oscillate completed its legal opinion, thereby enabling it to lawfully invest in the medical psychedelics industry and positioned as one of the first listed investment issuers within U.K. capital markets permitted to invest in opportunities consistent with the legal opinion.
Investment Positions & Commercial Activity Post 31 May 2021:
IGRAINE PLC (AQSE: KING)
28 June 2021
No. of Shares Held: 21,312,460
As a % of the Enlarged: 24.64%
About Igraine:
Chairman, Professor Sir Christopher Evans OBE
Professor Sir Christopher Evans is a renowned scientist and highly successful entrepreneur with numerous prestigious awards and medals for his work over the last 30 years during which time he has built more than 50 medical companies from start-up and floated 20 new medical businesses on stock markets in six different countries.
He has created 11 successful academic spin-outs and companies worth over $2.4 billion, and has raised $2.6 billion from disposals. He directed the raising of approximately $450 million for Merlin Biosciences Funds and $2.6 billion from disposals, including the sale of BioVex Group, Inc. to Amgen Inc. and Piramed Limited to Roche Group. Through Merlin Ventures Limited he co-founded and advised Biotech Growth Trust plc. Arakis Limited, one of the companies developed by Chris Evans, was sold to Sosei Co. Ltd for $187 million. Chris Evans has founded notable companies such